Comparative Pharmacology
Head-to-head clinical analysis: ERYZOLE versus OPHTHOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYZOLE versus OPHTHOCORT.
ERYZOLE vs OPHTHOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step.
OPHTHOCORT contains chloramphenicol, a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation; and hydrocortisone, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
Adults: 500 mg orally once daily for 3 consecutive days per month.
One drop into the affected eye(s) every 3-4 hours, or more frequently as needed. In severe cases, one drop every hour. Shake well before use.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in patients with normal renal function (creatinine clearance >60 mL/min). In severe renal impairment (CrCl <30 mL/min), half-life may extend to 12-18 hours.
Terminal elimination half-life: 2.5-3.5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for approximately 75% of the dose; fecal elimination is about 20%, with the remainder as biliary metabolites.
Renal (70-80% as unchanged drug), fecal (15-20% via biliary elimination), with minor metabolic clearance.
Category C
Category C
Antibiotic Combination
Ophthalmic Corticosteroid/Antibiotic Combination